Literature DB >> 32156607

Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020.

Rui Liu1, Huan Han1, Fang Liu2, Zhihua Lv1, Kailang Wu3, Yingle Liu3, Yong Feng4, Chengliang Zhu5.   

Abstract

BACKGROUND: There's an outbreak of a novel coronavirus (SARS-CoV-2) infection since December 2019, first in China, and currently with more than 80 thousand confirmed infection globally in 29 countries till March 2, 2020. Identification, isolation and caring for patients early are essential to limit human-to-human transmission including reducing secondary infections among close contacts and health care workers, preventing transmission amplification events. The RT-PCR detection of viral nucleic acid test (NAT) was one of the most quickly established laboratory diagnosis method in a novel viral pandemic, just as in this COVID-19 outbreak.
METHODS: 4880 cases that had respiratory infection symptoms or close contact with COVID-19 patients in hospital in Wuhan, China, were tested for SARS-CoV-2 infection by use of quantitative RT-PCR (qRT-PCR) on samples from the respiratory tract. Positive rates were calculated in groups divided by genders or ages.
RESULTS: The positive rate was about 38% for the total 4880 specimens. Male and older population had a significant higher positive rates. However, 57% was positive among the specimens from the Fever Clinics. Binary logistic regression analysis showed that age, not gender, was the risk factor for SARS-CoV-2 infection in fever clinics.
CONCLUSIONS: Therefore, we concluded that viral NAT played an important role in identifying SARS-CoV-2 infection.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  COVID-19; Nucleic acid test; Positive rate; SARS-CoV-2

Mesh:

Substances:

Year:  2020        PMID: 32156607      PMCID: PMC7094385          DOI: 10.1016/j.cca.2020.03.009

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


Introduction

Since December 2019, an epidemic Coronavirus disease (COVID-19) caused by novel coronavirus (SARS-CoV-2) infection has occurred unexpectedly in China. Till March 2, 2020, more than 80 thousand confirmed cases have been reported in China. Of these cases, 49 thousand were identified in Wuhan City. Identification, isolation and caring for patients early are essential to limit human-to-human transmission including reducing secondary infections among close contacts and health care workers, preventing transmission amplification events. Following the national recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 5th edition) and current status of clinical practice in Hubei Province, RT-PCR analysis was used to detect the causative virus from respiratory secretions. However, some investigators and clinical doctors argued that CT imaging should be served to identify the SARS-CoV-2 infection instead, since quite a bit cases showed progressive multiple peripheral ground-glass opacities in both lungs even the RT-PCR results were negative [1], [2]. Since RT-PCR was one of the most quickly established laboratory diagnosis method in a novel viral pandemic, just as this COVID-19, it served efficiently to confirm a viral infection within 2 h. During the early Feb, the need of detect increased dramatically up to 10 thousands of samples per day in Wuhan City. But to what extend was this RT-PCR based viral nucleic acid test (NAT) could reflect the real SARS-CoV-2 infection? Therefore in this study, we retrospectively analysed NAT test of 4880 cases from Jan 22 to Feb 14, 2020 in Renmin Hospital of Wuhan University. All the cases were suspected of SARS-CoV-2 infection because of, (1) typical respiratory infection symptoms such as fever, cough and dyspnoea, or (2) close contact with a COVID-19 patient. RT-PCR were performed to detect ORF1ab and NP genes fragments from respiratory specimens, including nasal and pharyngeal swabs (NPS), bronchoalveolar lavage fluid (BLF) and sputum.

Materials and methods

Data collection

4880 cases from Jan 22 to Feb 14 were tested for SARS-CoV-2 infection in Renmin Hospital of Wuhan University, who were suspected or at high risk of infection because of, (1) typical respiratory infection symptoms such as fever, cough and hard breath, or (2) close contact with a SARS-CoV-2 patients. Among these cases, 2251 were man (46.13%), 2629 were women (53.87%). The Median Age was 50 years (IQR = 27). Groups based on age: 18–29 (n = 482), 30–39 (n = 1097), 40–49 (n = 841), 50–59 (n = 1011), 60–69 (n = 886), >70 (n = 563). This study was approved by the Ethics Committee of the Renmin Hospital of Wuhan University (WDRM2020-K066) and the need for informed consent was waived.

RT-PCR detection

The presence of SARS-CoV-2 in respiratory specimens was detected by real-time RT-PCR amplification of SARS-CoV-2 open reading frame 1ab (ORF1ab), nucleocapsid protein (NP) genes fragments using kits provided by Shanghai Huirui Biotechnology Co., Ltd. Conditions for amplifications were 50 °C for 15 min, 95 °C for 3 min, followed by 45 cycles of 95 °C for 15 s and 60 °C for 30 s. As previously described [3], when two targets (ORF1ab, NP) tested positive by specific real-time RT-PCR, the case would be considered to be laboratory-confirmed. A cycle threshold value (Ct-value) less than 37 was defined as a positive test, and a Ct-value of 40 or more was defined as a negative test. A medium load, defined as a Ct-value of 37 to less than 40, required confirmation by retesting.

Statistical analysis

Statistical analyses were done by using the SPSS25.0 software. Chi-square test was used to compare inter-group differences, and binary logistic regression analysis was performed to analyze the risk factors for SARS-CoV-2 prevalence. Statistical significance was defined as P < 0.05.

Results

Nasal and pharyngeal swabs showed poor positive rate in 4880 cases

1875 out of 4880 (38.42%) were positive by RT-PCR-based NAT test with their respiratory specimens. Among this, 39.80% were positive for SARS-CoV-2-NP and 40.98% for SARS-CoV-2-ORF1ab (Table 1 ). We could see that the bronchoalveolar lavage fluid (BLF), exhibited the most highest positive rate of 100% for SARS-CoV-2 ORF1ab gene (n = 5). The nasal and pharyngeal swabs (NPS) samples (n = 4818) showed a poor positive rate of 38.25%. The Sputum exhibited a 49.12% positive rate.
Table 1

SARS-CoV-2 NAT positive rate of 4880 cases with their respiratory specimens by RT-PCR.

Nuclear AcidSputum(n = 57)
Bronchoalveolar Lavage Fluid(n = 5)
Nasal and Pharyngeal Swabs(n = 4818)
TotalTotal Positive Rate
nPositive RatenPositive RatenPositive Rate
NP2849.12%480.00%191039.64%194239.80%
ORF1ab2950.88%5100.00%196640.81%200040.98%
Double positive2849.12%480.00%184338.25%187538.42%
SARS-CoV-2 NAT positive rate of 4880 cases with their respiratory specimens by RT-PCR.

Male had a higher positive rate than female in the total 4880 cases

The male patients are 2251, female are 2629. There is no obvious gender difference during sample collection. But for male, 40.43% were positive while for female, 36.71% were positive (Table 2 ). The Positive Rate were significantly higher in Male than in Female cases (p < 0.01).
Table 2

SARS-CoV-2 NAT positive rate in Male and Female groups.

Nuclear AcidMale(n = 2251)
Female(n = 2629)
χ2p value
nPositive RatenPositive Rate
NP94341.89%99938.00%7.6720.006
ORF1ab96742.96%103339.29%6.7390.009
Double positive91040.43%96536.71%7.0950.008
SARS-CoV-2 NAT positive rate in Male and Female groups.

The positive rate increased in older cases

When we analyzed the positive rate according to age (Table 3 ), and we could see that positive rate increased from 24.90% (age 18–30) to 61.81% (age > 70).
Table 3

SARS-CoV-2 NAT positive rate in groups according to age.

Nuclear Acid18–2930–3940–4950–5960–69≥70χ2p value
(n = 482)(n = 1097)(n = 841)(n = 1011)(n = 886)(n = 563)
Gender rate229/253494/603389/452451/560417/469271/2923.0710.689
(M/F)
nCov-NP129280287446439361320.802<0.001
nCovORF1ab124286296461466367353.547<0.001
Double Positive120271278434424348306.946<0.001
Double Positive Rate24.90%24.70%33.06%42.93%47.86%61.81%
SARS-CoV-2 NAT positive rate in groups according to age.

Gender and age are two risk factors for SARS-CoV-2 infection

Binary logistic regression analysis showed that gender and age were two risk factor for SARS-CoV-2 infection (Table 4 ). Male and older people were more sensitive to the this novel virus infection (p < 0.05).
Table 4

Risks of SARS-CoV-2 positive rate upon Gender and Age.

Risk factorsRegression coefficientap valueodds ratio95% CI for coefficient
Gender0.1470.0161.1581.028–1.305
Age0.032<0.0011.0331.029–1.037

These are regression coefficients adjusted for gender and age. CI = confidence interval.

Risks of SARS-CoV-2 positive rate upon Gender and Age. These are regression coefficients adjusted for gender and age. CI = confidence interval.

Specimens from Fever Clinics exhibited significant higher positive rate

Why the positive rate in this 4880 cases were this low? Or did the viral NAT test fail to serve for the diagnosis in this pneumonia epidemic? Since the 4880 specimens conclude all cases during the period in the hospital, such as fever, cough and hard breath, or close contact with COVID-19 patient, we further analyzed data from adult fever clinics (n = 1707, Table 5 ). Notably, the positive rate of patients in fever clinics (57.00%) was significant higher than the rate of the total (38.42%).
Table 5

SARS-CoV-2 NAT positive rate of 1707 cases from Fever Clinics.

Nuclear AcidSputum(n = 14)
Bronchoalveolar Lavage Fluid(n = 3)
Nasal and Pharyngeal Swabs(n = 1690)
TotalTotal Positive Rate
nPositive RatenPositive RatenPositive Rate
NP1178.57%266.67%98057.99%99358.17%
ORF1ab1285.71%3100.00%103161.01%104661.28%
Double positive1178.57%266.67%96056.80%97357.00%
SARS-CoV-2 NAT positive rate of 1707 cases from Fever Clinics.

The age, not the gender, was the risk factor for SARS-CoV-2 infection in Fever Clinics

When we analyzed the positive rate between Male and Female cases from Fever Clinics, we did not observed significant difference. There were 499 positive male (57.69%) and 474 female (56.29%) from 1707 total Fever Clinics specimens. When we analyzed data in age-based groups in Fever Clinics, we could see the older had higher positive rate (Table 6 ). Positive rate in each group were 38.83%, 48.96%, 53.77%, 56.88%, 57.33% and 76.69%, which were significantly higher than the rate in the total 4880 cases.
Table 6

SARS-CoV-2 NAT positive rate in Fever Clinics grouped according to age.

Nuclear Acid18–2930–3940–4950–5960–69≥70χ2p value
(n = 103)(n = 241)(n = 292)(n = 385)(n = 450)(n = 236)
Gender rate58/45126/115152/140185/200224/226120/1162.9880.702
(M/F)
nCov-NP4111916122226418664.456<0.001
nCovORF1ab4112716823428918762.98<0.001
Double Positive4011815721925818158.835<0.001
Double Positive Rate38.83%48.96%53.77%56.88%57.33%76.69%
SARS-CoV-2 NAT positive rate in Fever Clinics grouped according to age. Binary logistic regression analysis showed that the age, not the gender, was the risk factor for SARS-CoV-2 infection in Fever Clinics. There was a quite special period that a large amount of patients rushed to health care centres or fever clinics because of panic in early Feb in Wuhan City, when a bigger amount of patients far beyond the capacity of laboratory testing. We analyzed positive percentage for SARS-CoV-2 infection in each week during 22th Jan to 14th Feb from Fever Clinics in Renmin Hospital. 63.87% (631 out of 988) were double positive for viral genes testing, which indicated a real high number of SARS-CoV-2 infection among this panic suspect population (see Table 7 ).
Table 7

SARS-CoV-2 NAT positive rate in Fever Clinics in different date periods.

Nuclear Acid22–29th Jan(n = 286)
30th Jan–6th Feb(n = 988)
7th–14th Feb(n = 433)
χ2p value
nPositive RatenPositive RatenPositive Rate
NP15253.15%64865.59%19344.57%58.205<0.001
ORF1ab16959.09%66867.61%20948.27%48.166<0.001
Double positive15253.15%63163.87%19043.88%51.148<0.001
SARS-CoV-2 NAT positive rate in Fever Clinics in different date periods.

Discussion

For the 2019 novel coronavirus disease (COVID-19), patients can be afebrile in the early stages of infection, with only chills and respiratory symptoms, but not always high temperature [4], [5], [6]. Elevated C-reactive protein (CRP) and lymphopenia are important factors. More and more evidence had shown distinct and complicated performance of COVID-19 as compared to SARS or MERS, which provided typical clinical symptoms for diagnosis [5]. Therefore, diagnosis of suspected SARS-CoV-2 caused pneumonia in Wuhan was based on clinical characteristics, chest imaging [1], [7], and the ruling out of common bacterial and viral pathogens that cause pneumonia as suggested by the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 6th edition). Here in this study, we analyzed recent 4880 cases by laboratory diagnosis of suspect SARS-CoV-2 infection in one hospital in Wuhan City, showing 38.42% positive percentage for total, but 57.00% positive in Fever Clinics. Relatively increased positive percentage in Fever Clinics suggested that the fever associated clinical symptoms were linked with viral NAT, at some degree. Interestingly, total positive percentage were associated with gender and age, while positive percentage in Fever Clinics was only associated with age, not gender. Therefore, consistent with other reports, we could conclude that for suspect SARS-CoV-2 infection, positive percentage would be higher in Male and Old, but in Fever Clinics, gender was not a risk factor. The epidemic seems to be spreading rapidly worldwide, especially in Korea, Italy and Iran. Based on the reasons mentioned above, we suggest that viral NAT is a rapid, easy conducted, and widely used laboratory diagnosis for SARS-CoV-2 infection, especially for Fever Clinics. Clinical characteristics, chest imaging and etiology testing based on viral genes RT-PCR should be combined to tell a confirmation [4], [8]. Since there exists infection with atypical symptoms, RT-PCR should be taken for several times just in case of fake negative results. For those countries who are facing an increased number of SARS-CoV-2 infection, we strongly suggest to prepare more reagents for SARS-CoV-2 NAT. Also, more laboratories and facilities should be trained and prepared for RT-PCR detection under a Biological Safety Protection 3-Level, just in case the horrible increasing requirements for detection that happened in early Feb in Wuhan, China.
  7 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR.

Authors:  Yicheng Fang; Huangqi Zhang; Jicheng Xie; Minjie Lin; Lingjun Ying; Peipei Pang; Wenbin Ji
Journal:  Radiology       Date:  2020-02-19       Impact factor: 11.105

3.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

4.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Authors:  Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 176.079

5.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

6.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

7.  Chest CT for Typical Coronavirus Disease 2019 (COVID-19) Pneumonia: Relationship to Negative RT-PCR Testing.

Authors:  Xingzhi Xie; Zheng Zhong; Wei Zhao; Chao Zheng; Fei Wang; Jun Liu
Journal:  Radiology       Date:  2020-02-12       Impact factor: 11.105

  7 in total
  185 in total

1.  Characteristics and diagnosis rate of 5630 subjects receiving SARS-CoV-2 nucleic acid tests from Wuhan, China.

Authors:  Na Shen; Yaowu Zhu; Xiong Wang; Jing Peng; Weiyong Liu; Feng Wang; Yanjun Lu; Liming Cheng; Ziyong Sun
Journal:  JCI Insight       Date:  2020-05-21

Review 2.  Microfluidic-based approaches for COVID-19 diagnosis.

Authors:  Hsuan-Yu Mu; Yu-Lun Lu; Tzu-Hung Hsiao; Jen-Huang Huang
Journal:  Biomicrofluidics       Date:  2020-12-08       Impact factor: 2.800

Review 3.  Laboratory Tests for COVID-19: A Review of Peer-Reviewed Publications and Implications for Clinical UIse.

Authors:  Daniel Shyu; James Dorroh; Caleb Holtmeyer; Detlef Ritter; Anandhi Upendran; Raghuraman Kannan; Dima Dandachi; Christian Rojas-Moreno; Stevan P Whitt; Hariharan Regunath
Journal:  Mo Med       Date:  2020 May-Jun

4.  Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version).

Authors:  Ying-Hui Jin; Qing-Yuan Zhan; Zhi-Yong Peng; Xue-Qun Ren; Xun-Tao Yin; Lin Cai; Yu-Feng Yuan; Ji-Rong Yue; Xiao-Chun Zhang; Qi-Wen Yang; Jianguang Ji; Jian Xia; Yi-Rong Li; Fu-Xiang Zhou; Ya-Dong Gao; Zhui Yu; Feng Xu; Ming-Li Tu; Li-Ming Tan; Min Yang; Fang Chen; Xiao-Ju Zhang; Mei Zeng; Yu Zhu; Xin-Can Liu; Jian Yang; Dong-Chi Zhao; Yu-Feng Ding; Ning Hou; Fu-Bing Wang; Hao Chen; Yong-Gang Zhang; Wei Li; Wen Chen; Yue-Xian Shi; Xiu-Zhi Yang; Xue-Jun Wang; Yan-Jun Zhong; Ming-Juan Zhao; Bing-Hui Li; Lin-Lu Ma; Hao Zi; Na Wang; Yun-Yun Wang; Shao-Fu Yu; Lu-Yao Li; Qiao Huang; Hong Weng; Xiang-Ying Ren; Li-Sha Luo; Man-Ru Fan; Di Huang; Hong-Yang Xue; Lin-Xin Yu; Jin-Ping Gao; Tong Deng; Xian-Tao Zeng; Hong-Jun Li; Zhen-Shun Cheng; Xiaomei Yao; Xing-Huan Wang
Journal:  Mil Med Res       Date:  2020-09-04

5.  Diagnosis of COVID-19, vitality of emerging technologies and preventive measures.

Authors:  Muhammad Asif; Yun Xu; Fei Xiao; Yimin Sun
Journal:  Chem Eng J       Date:  2021-05-07       Impact factor: 13.273

Review 6.  Point-of-care diagnostics for infectious diseases: From methods to devices.

Authors:  Chao Wang; Mei Liu; Zhifei Wang; Song Li; Yan Deng; Nongyue He
Journal:  Nano Today       Date:  2021-02-06       Impact factor: 20.722

7.  Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions.

Authors:  Daniel J Butler; Christopher Mozsary; Cem Meydan; David Danko; Jonathan Foox; Joel Rosiene; Alon Shaiber; Ebrahim Afshinnekoo; Matthew MacKay; Fritz J Sedlazeck; Nikolay A Ivanov; Maria Sierra; Diana Pohle; Michael Zietz; Undina Gisladottir; Vijendra Ramlall; Craig D Westover; Krista Ryon; Benjamin Young; Chandrima Bhattacharya; Phyllis Ruggiero; Bradley W Langhorst; Nathan Tanner; Justyna Gawrys; Dmitry Meleshko; Dong Xu; Peter A D Steel; Amos J Shemesh; Jenny Xiang; Jean Thierry-Mieg; Danielle Thierry-Mieg; Robert E Schwartz; Angelika Iftner; Daniela Bezdan; John Sipley; Lin Cong; Arryn Craney; Priya Velu; Ari M Melnick; Iman Hajirasouliha; Stacy M Horner; Thomas Iftner; Mirella Salvatore; Massimo Loda; Lars F Westblade; Melissa Cushing; Shawn Levy; Shixiu Wu; Nicholas Tatonetti; Marcin Imielinski; Hanna Rennert; Christopher E Mason
Journal:  bioRxiv       Date:  2020-05-01

8.  Development of a rapid and sensitive quantum dot nanobead-based double-antigen sandwich lateral flow immunoassay and its clinical performance for the detection of SARS-CoV-2 total antibodies.

Authors:  Yaofeng Zhou; Yuan Chen; Wenjuan Liu; Hao Fang; Xiangmin Li; Li Hou; Yuanjie Liu; Weihua Lai; Xiaolin Huang; Yonghua Xiong
Journal:  Sens Actuators B Chem       Date:  2021-05-21       Impact factor: 7.460

9.  Simple hemogram to support the decision-making of COVID-19 diagnosis using clusters analysis with self-organizing maps neural network.

Authors:  Alexandra A de Souza; Danilo Candido de Almeida; Thiago S Barcelos; Rodrigo Campos Bortoletto; Roberto Munoz; Helio Waldman; Miguel Angelo Goes; Leandro A Silva
Journal:  Soft comput       Date:  2021-05-17       Impact factor: 3.732

Review 10.  The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).

Authors:  Narasimha M Beeraka; SubbaRao V Tulimilli; Medha Karnik; Surya P Sadhu; Rajeswara Rao Pragada; Gjumrakch Aliev; SubbaRao V Madhunapantula
Journal:  Biomed Res Int       Date:  2021-06-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.